Project Grant R01CA310056
Award Date 5/11/26
Completion Date 4/30/31
Dollars Obligated $614K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,194,586 project grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The grant, awarded on September 30, 2023, will support a 3-year research project titled "COEVOLUTION OF METABOLISM AND IMMUNE MICROENVIRONMENT AS A DRIVER OF THERAPEUTIC RESPONSE AND METASTASIS IN CCRCC". Through this grant, the Sloan-Kettering Institute...
- Federal Project Grant Award Summary The National Cancer Institute awarded $292,028 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) beginning August 1, 2025, and concluding July 31, 2030. This five-year Project Grant supports research investigating genome instability associated with focal oncogene amplification (OA) and the development of therapeutic strategies to address treatment-resistant cancers. The research deliverables include...
- Federal Project Grant Award Summary The National Cancer Institute awarded $452,540 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for a project grant spanning May 1, 2026 through April 30, 2028. The funded research addresses innate and adaptive determinants of cytokine release syndrome (CRS) in chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. The project investigates the molecular mechanisms underlying CRS, a...
- Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $1.16M Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 5, 2025, with completion scheduled for May 31, 2030. This research project investigates the mechanisms of microhomology-mediated end-joining (MMEJ), a mutagenic DNA double-strand break repair pathway, with particular emphasis on its role during mitosis and its contribution to drug...
- This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
- Federal Grant Award Summary The National Cancer Institute awarded $727,732 to Sloan-Kettering Institute for Cancer Research on June 3, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a Phase IB/II clinical trial investigating combination therapy for dedifferentiated liposarcoma (DDLS). The primary deliverable is a clinical trial evaluating the efficacy and safety of palbociclib combined with the MEK inhibitor mirdametinib in patients with progressive DDLS, with an...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...